Home RxNorm 2665609 Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus] Drug identity information. FDA.report links public drug records from RxNav, DailyMed, FDA NDC, Drugs@FDA, and related public sources where available. This page is informational only and is not medical, prescribing, or regulatory advice.
RxCUI 2665609
RxNorm name Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]
Display name Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]
Full name Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]
Term type SBD
Status DailyMed mapping
Updated 2026-06-04 23:39:22 Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 125761 CYFENDUS Anthrax Vaccine Adsorbed, Adjuvanted 351(a) Rx 2026-08-01
RxNav Current And Historical NDCs# RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.
No records found.
UNII Substances# UNII substance links page 1 of 1 · 0 matching rows.
No records found.
DailyMed RxNorm Mappings# unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.
Set ID, RxNorm mappings, Terms table Set ID RxNorm mappings Terms SPL version Label Effective d4f29180-7c76-40ac-9341-cf62702c4090 CYFENDUS 0.1 MG/ML Injectable Suspension [PSN] · Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus] [SBD] · Cyfendus 0.1 MG/ML Injectable Suspension [SY] 3 6 These highlights do not include all the information needed to use CYFENDUS safely and effectively. See full prescribing information for CYFENDUS . CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted) injectable suspension, for intramuscular use Initial U.S. Approval: 2023 20260225